New cocktail attack on stubborn colon cancer
NCT ID NCT07622550
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a combination of two targeted drugs (fruquintinib and serplulimab) plus chemotherapy as a first treatment for 80 people with advanced colorectal cancer that has RAS or BRAF mutations. The goal is to see if this mix can delay cancer growth and improve survival. Participants will receive the drugs in cycles, followed by maintenance therapy if their disease is controlled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fruquintinib, serplulimab, and chemotherapy (oxaliplatin and capecitabine)
What this could lead to
If successful, this could offer a new first-line treatment option for people with a hard-to-treat form of advanced colorectal cancer.
What could go wrong
This is a small, early-phase (phase 2) trial with no control group, so results may not be definitive. The drug combination may cause significant side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (CRC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Changshu No.2 People's Hospital
Suzhou, Jiangsu, 215000, China
Contact Phone: •••-•••-••••
-
Changzhou Tumor Hospital (Changzhou Fourth People's Hospital)
Changzhou, Jiangsu, 213000, China
Contact Phone: •••-•••-••••
-
First Affiliated Hospital of Nanjing Medical Unviersity
Nanjing, Jiangsu, 210000, China
Contact Phone: •••-•••-••••
-
Huaian First People's Hospital
Huai'an, Jiangsu, 223000, China
Contact Phone: •••-•••-••••
-
Jiangsu Cancer Institute & Hospital
Nanjing, Jiangsu, 210000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Jiangyin People's Hospital
Wuxi, Jiangsu, 214400, China
Contact Phone: •••-•••-••••
-
Liyang People's Hospital
Changzhou, Jiangsu, 213000, China
Contact Phone: •••-•••-••••
-
Nantong University Cancer Hospital
Nantong, Jiangsu, 226000, China
Contact Phone: •••-•••-••••
-
Suzhou Municipal Hospital
Suzhou, Jiangsu, 215000, China
Contact Phone: •••-•••-••••
-
The First People's Hospital of Changzhou
Changzhou, Jiangsu, 213000, China
-
The First People's Hospital of Lianyungang
Lianyungang, Jiangsu, 222000, China
-
The First People's Hospital of Nantong
Nantong, Jiangsu, 226000, China
Contact Phone: •••-•••-••••
-
Wuxi Huishan District People's Hospital
Wuxi, Jiangsu, 214000, China
Contact Phone: •••-•••-••••
-
Xuzhou First People's Hospital
Xuzhou, Jiangsu, 221000, China
Contact Phone: •••-•••-••••
-
Yangzhou University Affiliated Jiangdu People's Hospital
Yangzhou, Jiangsu, 225000, China
Contact Phone: •••-•••-••••
-
Yizheng People's Hospital
Yangzhou, Jiangsu, 225000, China